Hematology/Oncology

Top Story

Studies of immunotherapy for prostate cancer yield encouraging results

Studies of immunotherapy for prostate cancer yield encouraging results
June 22, 2018

Ruxolitinib shows promising response rate for graft-versus-host disease

June 22, 2018
A phase 2 trial of ruxolitinib met its primary endpoint of overall response rate for the treatment of patients with steroid-refractory graft-versus-host disease…

NBTXR3 with radiotherapy doubles responses for soft tissue sarcoma

June 22, 2018
A trial assessing NBTXR3 plus radiotherapy met its primary endpoint of improved pathologic complete response rate compared with standard of care among patients with soft…
In the Journals

Trump supporters linked to chronic opioid use

June 22, 2018
There were parallels between voting for Donald J. Trump in the 2016 presidential election and chronic opioid use, according to findings recently published in JAMA
Feature

Study of t(11;14) translocation may offer ‘valuable real-world evidence’ to advance myeloma treatment

June 22, 2018
The International Myeloma Foundation has collaborated with AbbVie on a retrospective chart review study to assess outcomes of patients with multiple myeloma who have…
More Headlines »
CME ABIM MOC

Ace the Case: A 48-Year-Old Woman Confused About a Diagnosis of Leukemia

There is no commercial support for this activity.

This “Ace the Case” activity will utilize a case study to discuss the assessment and management of a 48-year-old woman…
More »
Video
Meeting News

VIDEO: Lenvatinib-pembrolizumab shows promise in several cancer types

June 22, 2018
More »
Resource Centers
ASCO Annual Meeting

ASCO Annual Meeting

CME

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

The integration of immune checkpoint inhibitors into treatment algorithms for patients with bladder cancer who have…
More »
Current Issues
View the Current Issue
HemOnc Today